IIM
HRTX icon

INTECH Investment Management’s Heron Therapeutics HRTX Stock Holding History

INTECH Investment Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.7K Sell
42,150
-17,219
-29% -$20K ﹤0.01% 2040
2025
Q4 		$77.2K Sell
59,369
-13,996
-19% -$17.3K ﹤0.01% 2205
2025
Q3 		$92.4K Sell
73,365
-21,446
-23% -$34K ﹤0.01% 2289
2025
Q2 		$196K Buy
94,811
+13,725
+17% +$28K ﹤0.01% 2095
2025
Q1 		$178K Buy
81,086
+22,844
+39% +$44.3K ﹤0.01% 2134
2024
Q4 		$89.1K Buy
58,242
+22,254
+62% +$36.1K ﹤0.01% 2234
2024
Q3 		$71.6K Buy
+35,988
New +$85.9K ﹤0.01% 1939

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

INTECH Investment Management's HRTX Position: Q1 2026 in Review

INTECH Investment Management reduced its Heron Therapeutics (HRTX) stake by 29% in Q1 2026, selling an estimated $20K and leaving 42,150 shares worth $33.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2040.

INTECH Investment Management first reported a position in HRTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $196K in Q2 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • INTECH Investment Management held 42,150 shares of Heron Therapeutics worth $33.7K as of Q1 2026.
  • INTECH Investment Management sold 17,219 Heron Therapeutics shares in Q1 2026, an estimated $20K.
  • Heron Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q1 2026, its #2040 holding.
  • INTECH Investment Management first reported a position in Heron Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • INTECH Investment Management's Heron Therapeutics position peaked at $196K in Q2 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.